OOIR: Observatory of International Research

Papers

(The median citation count of Best Practice & Research Clinical Haematology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Contemporary and future strategies in polycythemia vera	77
HLA typing: A review of methodologies and clinical impact on haematopoietic cell transplantation	40
The role of randomized controlled trials, registries, observational databases in evaluating new interventions	37
Asparaginase dosing for obese patients with acute lymphoblastic leukemia and factors that contribute to outcomes	35
“The state of the science” of childhood, adolescent and young adult Non Hodgkin Lymphoma (NHL)	34
What are the long-term complications of pediatric ALL treatments and how can they be mitigated? Perspectives on long-term consequences of curative treatment in childhood ALL	25
Reducing barriers of access and care related to hematopoietic cell transplantation and cellular therapy: The mission-driven role of the national marrow donor program	24
Coagulopathy in COVID-19 and anticoagulation clinical trials	24
Allogeneic “Off-the-Shelf” CAR T cells: Challenges and advances	22
Endpoint selection and evaluation in hematology studies	22
The presentation of results from studies in clinical haematology	21
Take a spin: Apheresis in the care of adult leukaemia patients	20
Editorial Board	15
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma	14
How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms	12
Creating a GMP cell processing program: A focus on quality and regulation	12
Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults	12
Targeted cellular therapy for treatment of relapsed or refractory leukemia	11
Vaccine-induced immune thrombotic thrombocytopenia	11
The international cooperative Gaucher group (ICCG) Gaucher registry	10
Principles of cost-effectiveness studies and their use in haematology	10
Applications and prospects of molecularly targeted drugs combined with CAR-T cell therapy to treat multiple myeloma	10
Accelerated and blast phase myeloproliferative neoplasms	10
Dysregulation of Protein S in COVID-19	10
Cytogenomics of B-cell non-Hodgkin lymphomas: The “old” meets the “new”	10

What should be done and what should be avoided when comparing two treatments?	9
Editorial Board	9
Late effects and frontline treatment selection for children with non-Hodgkin lymphoma	8
Is HLA-E with its receptors an immune checkpoint or an antigenic determinant in allo-HCT?	8
Prevention and treatment of COVID-19 in patients with benign and malignant blood disorders	8
The role of registries in hematological disorders	8
Worldwide sources of data in haematology: Importance of clinician-biostatistician collaboration	8
Hodgkin Lymphoma: A disease shaped by the tumor micro- and macroenvironment	7
The analysis of multiple outcomes, multiple variables and variables selection in hematopoietic cell transplantation studies	7
Handling missing covariate data in clinical studies in haematology	7
Addressing symptom burden in myeloproliferative neoplasms	7
Anti-GM-CSF autoantibodies in myeloid leukemias	7
A reflection on Arnold Caplan, the father of MSC	7
Corrigendum to “Precision immunomodulation: Understanding and harnessing cytokine pathways to treat and prevent immune-related adverse events (irAEs)” [Best Pract Res Clin Haematol 38 2 2025]	7
Human mesenchymal stem cell therapy: Potential advances for reducing cystic fibrosis infection and organ inflammation	7
Editorial Board / Aims & Scope	7
CAR assembly line: Taking CAR T-cell manufacturing to the next level	6
Recent progress in acute leukemia and myelodysplasia	6
The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia	6
Corrigendum to “Endpoint selection and evaluation in hematology studies” [Best Pract Res Clin Haematol 36 (2023) 101479]	6
Cytokines in hematopoietic cell transplantation and related cellular therapies	6
What is relative survival and what is its role in haematology?	5
Relevance of donor-specific HLA antibodies in hematopoietic cell transplantation	5
Corrigendum to “Designing and conducting a clinical trial in blood and marrow transplantation” [Best Pract Res Clin Haematol 36 (2023) 101471]	5
Measurable residual disease in patients undergoing allogeneic transplant for acute myeloid leukemia	5
Therapeutic initiatives using mesenchymal stem cells and other novel cells in hematology	5
The most frequent HLA alleles around the world: A fundamental synopsis	5
When to use which molecular prognostic scoring system in the management of patients with MDS?	5
Cytogenetics and genomics in CML and other myeloproliferative neoplasms	5
Considerations to comprehensive care for the older individual with myelofibrosis	5
SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care	5
Donor lymphocyte infusion in Acute Myeloid Leukemia	4
Diagnosis and management of ALK-positive anaplastic large cell lymphoma in children and adolescents	4
COVID-19 and antiphospholipid antibodies	4
Preface of special edition “Biostatistics in clinical haematology”	4
Diagnosis and management of mature B-cell lymphomas in children, adolescents, and young adults	4
Diagnosis and management of rare paediatric Non-Hodgkin lymphoma	4
Interfering with KIR and NKG2A immune checkpoint axes to unleash NK cell immunotherapy	4
The correlations among racial/ethnic groups, hypertriglyceridemia, thrombosis, and mortality in hospitalized patients with COVID-19	4
CARs for lymphoma	4
Editorial Board / Aims & Scope	4
Shape of the art: TCR-repertoire after allogeneic hematopoietic cell transplantation	4
Editorial Board	3
COVID-19: A hematological perspective	3
Designing and conducting a clinical trial in blood and marrow transplantation	3
Advancing MSC therapy: The next generation of potent mesenchymal stromal cells for systemic autoimmune rheumatic diseases	3
Research progress of targeted BCMA CAR-T therapy for relapsed/refractory multiple myeloma antigen-negative relapse	3
The Collaborative Biobank (CoBi): Donor and recipient samples & data to facilitate future research on hematopoietic cell transplantation	3
Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults	3
HLA-DM and HLA-DO interplay for the peptide editing of HLA class II in healthy tissues and leukemia	3

Consolidation chemotherapy in AML: Are we playing with a full deck of cards?	3
Cytokines in transplantation tolerance	3
Germline predisposition to myeloid neoplasms: Characteristics and management of high versus variable penetrance disorders	3
Cytokine therapy of acute radiation syndrome	3
Editorial Board / Aims & Scope	3
The best GVHD prophylaxis: Or at least progress towards finding it	3
Redox stress in COVID-19: Implications for hematologic disorders	3
Editorial Board	3
Using real-world evidence in haematology	3
Mesenchymal stem cells in hematology: Therapeutic initiatives and future directions	3